Although prophylactic antiviral therapy has recently been shown to prevent HBV reactivation in patients with HBsAg-negative/anti-HBc-positive lymphoma [17], the role of antiviral prophylaxis is unknown in HBsAg-negative patients with HCC. This evidence concerns the gene KRT88P and lymphoma.